Author

J. S. Gerke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Pathology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Assay:bulk RNA-seq· 7 Approach:statistical model· 7 Research Focus:differential expression· 5 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

G. Sannino· 9 shared M. F. Orth· 9 shared A. Marchetto· 8 shared J. Li· 8 shared J. Musa· 8 shared S. Ohmura· 8 shared T. G. P. Grunewald· 8 shared T. Kirchner· 8 shared

Activity by Year

2017-2019 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersCancer Biology

G. Sannino

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

J. Musa, F. Cidre-Aranaz, M.-M. Aynaud, M. F. Orth, O. Mirabeau, M. Varon, S. Grossetete, D. Surdez, S. Ohmura, J. S. Gerke, A. Marchetto, M. Dallmayer, M. C. Baldauf, M. Gartlgruber, F. Westermann, , T. G. P. Grunewald

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

Nature Communications · Sep 11, 2019Peer-reviewedCancer Biology

Focal adhesion kinase confers pro-migratory and anti apoptotic properties and is a potential therapeutic target in Ewing sarcoma

K. Steinestel, E.-P. Jansen, M. Trautmann, U. Dirksen, J. Rehkamper, J.-H. Mikesch, J. S. Gerke, M. F. Orth, G. Sannino, E. Wardelmann, T. G. P. Grunewald, W. Hartmann

This study shows FAK promotes migration and prevents apoptosis in Ewing sarcoma via Y397 phosphorylation, suggesting FAK inhibitors could target metastasis.

bioRxiv · Apr 12, 2019Cancer Biology

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

A. Marchetto, S. Ohmura, M. F. Orth, J. Li, F. S. Wehweck, M. M. L. Knott, S. Stein, D. Saucier, C. Arrigoni, J. S. Gerke, M. C. Baldauf, J. Musa, M. Dallmayer, T. L. B. Hoelting, M. Moretti, , T. G. P. Grunewald

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

bioRxiv · Mar 14, 2019Cancer Biology

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

J. S. Gerke, M. F. Orth, Y. Tolkach, L. Romero-Perez, F. S. Wehweck, S. Stein, J. Musa, M. M. L. Knott, T. L. B. Hoelting, J. Li, G. Sannino, A. Marchetto, S. Ohmura, F. Cidre-Aranaz, M. Mueller-Nurasyid, , T. G. P. Grunewald

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

bioRxiv · Feb 10, 2019Cancer Biology

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

G. Sannino, A. Marchetto, A. Ranft, S. Jabar, C. Zacherl, R. Alba-Rubio, S. Stein, F. S. Wehweck, M. M. Kiran, T. L. B. Hoelting, J. Musa, L. Romero-Perez, F. Cidre-Aranaz, M. M. L. Knott, J. Li, , T. G. P. Grunewald

bioRxiv · Dec 17, 2018Pathology

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

M. Dallmayer, J. Li, S. Ohmura, R. Alba-Rubio, M. C. Baldauf, T. L. B. Hoelting, J. Musa, M. M. L. Knott, S. Stein, F. Cidre-Aranaz, F. S. Wehweck, L. Romero-Perez, J. S. Gerke, M. F. Orth, A. Marchetto, , T. G. P. Grunewald

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

bioRxiv · Dec 8, 2018Cancer Biology

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

M. F. Orth, J. S. Gerke, T. Knosel, A. Altendorf-Hofmann, J. Musa, R. Alba Rubio, S. Stein, M. Dallmayer, M. C. Baldauf, A. Marchetto, G. Sannino, S. Ohmura, J. Li, M. Hakozaki, T. Kirchner, , T. G. P. Grunewald

This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.

bioRxiv · Mar 31, 2018Pathology

Systematic identification of cancer-specific MHC-binding peptides with RAVEN

M. C. Baldauf, J. S. Gerke, A. Kirschner, F. Blaeschke, M. Effenberger, K. Schober, R. Alba Rubio, T. Kanaseki, M. M. Kiran, M. Dallmayer, J. Musa, N. Akpolat, A. N. Akatli, F. C. Rosman, O. Ozen, , T. G. Grunewald

The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.

bioRxiv · Sep 24, 2017Immunology

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets

M. C. Baldauf, M. F. Orth, M. Dallmayer, A. Marchetto, J. S. Gerke, R. Alba Rubio, M. M. Kiran, J. Musa, M. M. L. Knott, S. Ohmura, J. Li, N. Akpolat, A. N. Akatli, O. Ozen, U. Dirksen, , T. G. P. Grunewald

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.

bioRxiv · Jul 2, 2017Pathology